• 1. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

Introduction to N-(3-pyridinylmethyl)-2-butanamine hydrochloride (CAS No. 869941-70-8)

N-(3-pyridinylmethyl)-2-butanamine hydrochloride, with the chemical formula corresponding to its CAS number 869941-70-8, is a compound of significant interest in the field of pharmaceutical chemistry. This compound belongs to a class of molecules that exhibit diverse biological activities, making it a subject of extensive research and development. The N-(3-pyridinylmethyl)-2-butanamine hydrochloride structure incorporates a pyridine moiety, which is well-known for its role in many bioactive molecules, alongside an amine group that contributes to its pharmacological properties.

The< strong>pyridine ring in N-(3-pyridinylmethyl)-2-butanamine hydrochloride is a key feature that contributes to its interaction with biological targets. Pyridine derivatives are widely recognized for their ability to modulate various enzymatic and receptor systems, making them valuable in the development of drugs targeting neurological disorders, cardiovascular diseases, and inflammatory conditions. The presence of the< strong>3-pyridinylmethyl substituent enhances the compound's solubility and bioavailability, which are critical factors in drug design.

In recent years, there has been growing interest in the development of novel therapeutic agents that leverage the< strong>hydrochloride salt form of small molecules. The hydrochloride salt form improves the stability and bioavailability of the parent compound, making it more suitable for pharmaceutical applications. N-(3-pyridinylmethyl)-2-butanamine hydrochloride exemplifies this trend, as it combines the benefits of the pyridine-based scaffold with the advantages of the hydrochloride salt.

The pharmacological profile of N-(3-pyridinylmethyl)-2-butanamine hydrochloride has been extensively studied in various preclinical models. Research indicates that this compound exhibits potent activity against several biological targets, including enzymes and receptors involved in neurotransmitter regulation. Specifically, studies have shown that it may interact with< strong>D2 dopamine receptors, which are implicated in conditions such as Parkinson's disease and schizophrenia. The compound's ability to modulate these receptors makes it a promising candidate for further investigation in neuropharmacology.

Moreover, the< strong>3-pyridinylmethyl group in N-(3-pyridinylmethyl)-2-butanamine hydrochloride has been found to enhance binding affinity to certain enzymes, leading to increased pharmacological efficacy. This property is particularly relevant in the context of drug design, where optimizing binding interactions is crucial for achieving desired therapeutic outcomes. The compound's structure also suggests potential interactions with other biological targets, such as ion channels and G-protein coupled receptors (GPCRs), which are involved in a wide range of physiological processes.

Recent advancements in computational chemistry have enabled more accurate predictions of the pharmacokinetic and pharmacodynamic properties of N-(3-pyridinylmethyl)-2-butanamine hydrochloride. Molecular modeling studies have revealed insights into its binding mode with biological targets, providing a foundation for rational drug design. These computational approaches have been instrumental in identifying key structural features that contribute to the compound's activity, such as hydrogen bonding interactions and aromatic stacking phenomena.

The synthesis of N-(3-pyridinylmethyl)-2-butanamine hydrochloride involves multi-step organic reactions that require careful optimization to ensure high yield and purity. The< strong>N-(3-pyridinylmethyl) portion of the molecule is typically introduced through nucleophilic substitution reactions or cross-coupling techniques, while the amine group is subsequently converted into its hydrochloride salt form. Advances in synthetic methodologies have made it possible to produce this compound on a scalable basis, facilitating further research and development efforts.

In clinical settings, N-(3-pyridinylmethyl)-2-butanamine hydrochloride is being evaluated for its potential therapeutic applications. Preliminary studies suggest that it may have utility in treating conditions characterized by dysregulation of neurotransmitter systems. For instance, its ability to modulate dopamine receptor activity could make it a valuable tool in managing symptoms associated with neurological disorders. Additionally, its interactions with other biological targets open up possibilities for applications in areas such as pain management and anti-inflammatory therapy.

The< strong>hydrochloride salt form of N-(3-pyridinylmethyl)-2-butanamine hydrochloride offers several advantages over other formulations. Its improved solubility enhances oral bioavailability, while its stability ensures consistent performance during storage and transportation. These attributes make it a favorable candidate for further clinical development. Furthermore, the compound's favorable pharmacokinetic profile suggests that it may exhibit minimal side effects when administered at therapeutic doses.

Ongoing research continues to explore the full potential of N-(3-pyridinylmethyl)-2-butanamine hydrochloride in various therapeutic contexts. Investigational studies are focusing on elucidating its mechanism of action and identifying potential drug-drug interactions. These efforts are crucial for ensuring safe and effective use of the compound in clinical practice. Additionally, translational research is underway to bridge the gap between preclinical findings and clinical applications.

The future prospects for N-(3-pyridinylmethyl)-2-butanamine hydrochloride are promising, given its unique structural features and demonstrated biological activity. As our understanding of molecular interactions continues to evolve, this compound may find new applications across multiple therapeutic areas. Collaborative efforts between academic researchers and pharmaceutical industry professionals will be essential in realizing its full potential as a therapeutic agent.

• 1185302-30-0(Cyclopentyl-pyridin-3-ylmethyl-amine dihydrochloride)
• 626210-37-5(Cyclopentyl-pyridin-3-ylmethyl-amine)
• 183609-18-9(N-(Pyridin-3-ylmethyl)cyclopropanamine)
• 1420812-25-4(4-N-(Pyridin-3-ylmethyl)cyclohexane-1,4-diamine;hydrochloride)
• 19730-12-2((propan-2-yl)(pyridin-3-ylmethyl)amine)
• 1158468-90-6(N-(Pyridin-3-ylmethyl)cyclopropanamine hydrochloride)
• 179055-42-6(N-(3-Pyridinylmethyl)cycloheptanamine Hydrochloride)
• 185509-76-6(N-(Pyridin-3-ylmethyl)cyclobutanamine)
• 19730-13-3(propyl[(pyridin-3-yl)methyl]amine)
• 97247-37-5(N-(Pyridin-3-ylmethyl)cyclohexanamine)